GENCEPT 10/11-28
Clinical safety rating
cautionComprehensive clinical and safety monograph for GENCEPT 10/11-28 (GENCEPT 10/11-28).
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
| Metabolism | Ethinyl estradiol: primarily CYP3A4; Levonorgestrel: CYP3A4, undergoes reduction and sulfation. |
| Excretion | Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized. |
| Half-life | Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days. |
| Protein binding | 98% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.8-1.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 90%, with minimal first-pass metabolism. |
| Onset of Action | Oral administration: 2-3 hours for plasma concentration to reach therapeutic levels. |
| Duration of Action | Duration is approximately 24 hours due to once-daily dosing, with sustained plasma levels throughout the day. |
| Molecular Weight | 376.5 |
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. In severe renal impairment (GFR <30 mL/min), use with caution due to potential fluid retention and hypertension. |
| Liver impairment | Contraindicated in patients with Child-Pugh class B or C hepatic impairment (moderate to severe). In mild hepatic impairment (Child-Pugh class A), use with caution due to altered hormone metabolism. |
| Pediatric use | Not indicated for use in pediatric patients before menarche. For post-menarche adolescents, follow same dosing as adults. |
| Geriatric use | Not indicated for use in women above 55 years of age due to increased risk of thromboembolic events and lack of efficacy data. |
| 1st trimester | Use only if clearly needed. Contraception counseling recommended due to teratogenic risk of combined hormonal components. |
| 2nd trimester | Use only if clearly needed. May increase risk of venous thromboembolism. |
| 3rd trimester | Use only if clearly needed. May increase risk of venous thromboembolism. |
Clinical note
Comprehensive clinical and safety monograph for GENCEPT 10/11-28 (GENCEPT 10/11-28).
| Placental transfer | Estrogen and progestin components cross the placenta. Fetal exposure increases with higher doses. |
| Breastfeeding | Estrogens and progestins are excreted in breast milk in small amounts. May reduce milk production and composition. Use lowest effective dose, monitor infant for jaundice and growth. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | GENCEPT 10/11-28 contains gestodene and ethinylestradiol. Gestodene is a progestogen; ethinylestradiol is an estrogen. Combined hormonal contraceptives are contraindicated in pregnancy. First trimester: no increased risk of major birth defects based on epidemiological studies, but should not be used once pregnancy is confirmed. Second and third trimesters: no therapeutic indication; animal studies show fetotoxicity at high doses. Overall, use is not recommended in pregnancy. |
| Fetal Monitoring | Not applicable during pregnancy as drug is contraindicated. If inadvertent exposure occurs, no specific fetal monitoring is required beyond routine prenatal care. For postpartum use while breastfeeding, monitor infant for jaundice, weight gain, and developmental milestones; no routine maternal monitoring beyond standard contraceptive surveillance. |
| Fertility Effects | GENCEPT 10/11-28 is a combined oral contraceptive; it works by inhibiting ovulation and altering cervical mucus. Fertility returns promptly after discontinuation, typically within 1-2 cycles. No evidence of permanent fertility impairment. Long-term use does not affect future fertility or increase risk of infertility. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Women over 35 who smoke should not use this product.
| Serious Effects |
PregnancyHistory of or current venous thromboembolismKnown or suspected breast cancerUndiagnosed abnormal uterine bleedingLiver disease or impaired liver functionHypersensitivity to any component
| Precautions | Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI), Visual abnormalities (retinal thrombosis, papilledema), Hepatic neoplasia (benign/malignant liver tumors), Hypertension, Glucose intolerance/diabetes, Gallbladder disease, Depression, Bleeding irregularities |
| Food/Dietary | No specific food interactions are known. However, grapefruit juice may increase ethinyl estradiol levels; consider limiting grapefruit juice intake. Avoid excessive alcohol, as it may increase liver toxicity risk. |
| Clinical Pearls | GENCEPT 10/11-28 is a combination oral contraceptive containing ethinyl estradiol 10 mcg and drospirenone 3 mg (24 active tablets) plus placebo (4 tablets). It is used for contraception and treatment of moderate acne vulgaris in women who desire oral contraception. The 24-day active regimen increases ovarian suppression and reduces breakthrough bleeding. Drospirenone has antimineralocorticoid activity, which may cause hyperkalemia in patients with renal impairment, hepatic disease, or adrenal insufficiency. Monitor potassium in at-risk patients. Do not use with other potassium-sparing drugs. Avoid in women with hypertension, diabetes with vascular disease, or migraine with aura due to increased cardiovascular risk with low-dose EE. Consider starting on first day of menses for immediate contraceptive effect. |
| Patient Advice | Take one pill daily at the same time, in the order shown on the pack. Do not skip pills. · Use backup contraception (e.g., condoms) if you miss a pill, vomit within 3-4 hours after taking a pill, or have severe diarrhea. · Contact your doctor immediately if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice. · Cigarette smoking increases the risk of serious cardiovascular side effects. Do not smoke while taking this medication. · Store at room temperature, away from moisture and heat. |
Loading safety data…